These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 16749540)

  • 1. Children and adolescent exposures to atomoxetine hydrochloride reported to a poison control center.
    Stojanovski SD; Robinson RF; Baker SD; Casavant MJ; Hayes JR; Nahata MC
    Clin Toxicol (Phila); 2006; 44(3):243-7. PubMed ID: 16749540
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Atomoxetine: a review of its use in adults with attention deficit hyperactivity disorder.
    Simpson D; Plosker GL
    Drugs; 2004; 64(2):205-22. PubMed ID: 14717619
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dose-dependent Raynaud's phenomenon developing from use of atomoxetine in a girl.
    Gökçen C; Kutuk MO; Coşkun Ş
    J Child Adolesc Psychopharmacol; 2013 Aug; 23(6):428-30. PubMed ID: 23952193
    [No Abstract]   [Full Text] [Related]  

  • 4. Atomoxetine-induced mydriasis in a child patient.
    Bahali K; Ipek H; Yalcin O; Orum O
    Eur Child Adolesc Psychiatry; 2014 Dec; 23(12):1231-2. PubMed ID: 24213458
    [No Abstract]   [Full Text] [Related]  

  • 5. Suboptimal dosing of Strattera (atomoxetine) for ADHD patients.
    Clemow DB
    Postgrad Med; 2014 Sep; 126(5):196-8. PubMed ID: 25420287
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Atomoxetine: the first nonstimulant for the management of attention-deficit/hyperactivity disorder.
    Corman SL; Fedutes BA; Culley CM
    Am J Health Syst Pharm; 2004 Nov; 61(22):2391-9. PubMed ID: 15581262
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Once-daily atomoxetine for adult attention-deficit/hyperactivity disorder: a 6-month, double-blind trial.
    Adler LA; Spencer T; Brown TE; Holdnack J; Saylor K; Schuh K; Trzepacz PT; Williams DW; Kelsey D
    J Clin Psychopharmacol; 2009 Feb; 29(1):44-50. PubMed ID: 19142107
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety of non-therapeutic atomoxetine exposures--a national poison data system study.
    Monte AA; Ceschi A; Bodmer M
    Hum Psychopharmacol; 2013 Sep; 28(5):471-6. PubMed ID: 23861380
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical pharmacokinetics of atomoxetine.
    Sauer JM; Ring BJ; Witcher JW
    Clin Pharmacokinet; 2005; 44(6):571-90. PubMed ID: 15910008
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatic events associated with atomoxetine treatment for attention-deficit hyperactivity disorder.
    Bangs ME; Jin L; Zhang S; Desaiah D; Allen AJ; Read HA; Regev A; Wernicke JF
    Drug Saf; 2008; 31(4):345-54. PubMed ID: 18366245
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The effectiveness of atomoxetine in children, adolescents, and adults with ADHD. A systematic overview].
    Sevecke K; Battel S; Dittmann RW; Lehmkuhl G; Döpfner M
    Nervenarzt; 2006 Mar; 77(3):294, 297-300, 302-4 passim. PubMed ID: 16133434
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term treatment with atomoxetine for attention-deficit/hyperactivity disorder symptoms in children and adolescents with autism spectrum disorder: an open-label extension study.
    Harfterkamp M; Buitelaar JK; Minderaa RB; van de Loo-Neus G; van der Gaag RJ; Hoekstra PJ
    J Child Adolesc Psychopharmacol; 2013 Apr; 23(3):194-9. PubMed ID: 23578015
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An open-label, dose-titration tolerability study of atomoxetine hydrochloride in Japanese adults with attention-deficit/hyperactivity disorder.
    Takahashi M; Takita Y; Goto T; Ichikawa H; Saito K; Matsumoto H; Tanaka Y
    Psychiatry Clin Neurosci; 2011 Feb; 65(1):55-63. PubMed ID: 21265936
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Atomoxetine in the treatment of attention deficit hyperactivity disorder and suicidal ideation.
    Capuano A; Scavone C; Rafaniello C; Arcieri R; Rossi F; Panei P
    Expert Opin Drug Saf; 2014 Sep; 13 Suppl 1():S69-78. PubMed ID: 25171160
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [My child is so restless].
    Schlamp D
    MMW Fortschr Med; 2007 Mar; 149(10):39-40. PubMed ID: 17408047
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Open-label, dose-titration tolerability study of atomoxetine hydrochloride in Korean, Chinese, and Taiwanese adults with attention-deficit/hyperactivity disorder.
    Takahashi M; Goto T; Takita Y; Chung SK; Wang Y; Gau SS
    Asia Pac Psychiatry; 2014 Mar; 6(1):62-70. PubMed ID: 23857916
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of atomoxetine on cardiovascular functions and on QT dispersion in children with attention deficit hyperactivity disorder.
    Sert A; Gokcen C; Aypar E; Odabas D
    Cardiol Young; 2012 Apr; 22(2):158-61. PubMed ID: 21864451
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study.
    Quintana H; Cherlin EA; Duesenberg DA; Bangs ME; Ramsey JL; Feldman PD; Allen AJ; Kelsey DK
    Clin Ther; 2007 Jun; 29(6):1168-77. PubMed ID: 17692731
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of two different methods of initiating atomoxetine on the adverse event profile of atomoxetine.
    Greenhill LL; Newcorn JH; Gao H; Feldman PD
    J Am Acad Child Adolesc Psychiatry; 2007 May; 46(5):566-572. PubMed ID: 17450047
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized, double-blind, placebo-controlled clinical trial on once-daily atomoxetine in Taiwanese children and adolescents with attention-deficit/hyperactivity disorder.
    Gau SS; Huang YS; Soong WT; Chou MC; Chou WJ; Shang CY; Tseng WL; Allen AJ; Lee P
    J Child Adolesc Psychopharmacol; 2007 Aug; 17(4):447-60. PubMed ID: 17822340
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.